Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Fully bioresorbable vascular scaffolds: lessons learned and future directions
Fully bioresorbable scaffolds (BRS) were designed to overcome the limitations of metallic
drug-eluting stents, which permanently cage the vessel wall, thereby preventing normal …
drug-eluting stents, which permanently cage the vessel wall, thereby preventing normal …
Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures
This document is complementary to an Expert Review Document on Optical Coherence
Tomography (OCT) for the study of coronary arteries and atherosclerosis. 1 The goal of this …
Tomography (OCT) for the study of coronary arteries and atherosclerosis. 1 The goal of this …
A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions …
PW Serruys, B Chevalier, D Dudek, A Cequier… - The Lancet, 2015 - thelancet.com
Background Despite rapid dissemination of an everolimus-eluting bioresorbable scaffold for
treatment for coronary artery disease, no data from comparisons with its metallic stent …
treatment for coronary artery disease, no data from comparisons with its metallic stent …
Clinical impact of OCT findings during PCI: the CLI-OPCI II study
Objectives The goal of this study was to assess the clinical impact of optical coherence
tomography (OCT) findings during percutaneous coronary intervention (PCI). Background …
tomography (OCT) findings during percutaneous coronary intervention (PCI). Background …
Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month …
Background Absorbable scaffolds were designed to overcome the limitations of
conventional, non-absorbable metal-based drug-eluting stents. So far, only polymeric …
conventional, non-absorbable metal-based drug-eluting stents. So far, only polymeric …
Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective …
M Haude, R Erbel, P Erne, S Verheye, H Degen… - The Lancet, 2013 - thelancet.com
Background Bioabsorbable vascular scaffolds were developed to overcome limitations of
permanent bare-metal or drug-eluting coronary stents—ie, stent thrombosis (despite …
permanent bare-metal or drug-eluting coronary stents—ie, stent thrombosis (despite …
Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization?
Y Onuma, PW Serruys - Circulation, 2011 - ahajournals.org
Gruntzig in 1977 was a huge leap forward in cardiovascular medicine and undoubtedly will
always be remembered as a revolution in the field of revascularization. However, this …
always be remembered as a revolution in the field of revascularization. However, this …
From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade?
Drug-eluting bioresorbable scaffolds (BRSs) may in the near future change drastically the
landscape of percutaneous coronary revascularization. 1 In 1977, when Andreas Gruentzig …
landscape of percutaneous coronary revascularization. 1 In 1977, when Andreas Gruentzig …
Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench to bedside
Coronary stents have revolutionized the treatment of coronary artery disease. Compared
with balloon angioplasty, bare-metal stents (BMSs) effectively prevented abrupt vessel …
with balloon angioplasty, bare-metal stents (BMSs) effectively prevented abrupt vessel …
Comparison of everolimus-and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds
Background: The first CE-approved bioresorbable vascular scaffold (BVS) is effective at
treating simple lesions and stable coronary artery disease, but it has yet to be assessed …
treating simple lesions and stable coronary artery disease, but it has yet to be assessed …